Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer.

Trial Profile

Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Dendritic cell-activated cytokine-induced killer cells (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 03 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 08 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top